Cardiovascular Drugs Practice Questions

Q: All of the following are adverse effects of nicotinic acid except:

Pancreatitis. ***Pancreatitis*** - **Pancreatitis** is not a commonly reported adverse effect of nicotinic acid (niacin) therapy. - While other gastrointestinal side effects like nausea and vomiting can occur, pancreatic inflammation is not characteristic. *Vasodilation* - **Cutaneous flushing** and **vasodilation** are very common adverse effects of nicotinic acid, mediated by prostaglandin release. - This effect can cause a sensation of warmth, redness, and itching, especially at the start of therapy. *Liver dysfunction* - **Liver dysfunction**, including elevated liver enzymes and rare cases of **hepatotoxicity**, can occur with high doses of nicotinic acid. - Regular monitoring of liver function tests is recommended for patients on niacin therapy. *Hyperpigmentation* - **Hyperpigmentation**, particularly **acanthosis nigricans**, is a known cutaneous side effect of nicotinic acid. - This typically presents as dark, velvety patches on the skin, especially in skin fold areas.

Q: Which of the following is a renin inhibitor?

Remikiren. **Remikiren** - **Remikiren** is a direct **renin inhibitor** that acts by binding to the active site of renin, preventing its interaction with angiotensinogen. - This inhibition reduces the formation of **angiotensin I** and subsequently **angiotensin II**, leading to decreased blood pressure. *Losartan* - **Losartan** is an **Angiotensin II Receptor Blocker (ARB)**, meaning it blocks AT1 receptors, preventing angiotensin II from binding. - It does not inhibit renin activity directly but rather acts downstream in the **renin-angiotensin-aldosterone system (RAAS)**. *Benazepril* - **Benazepril** is an **Angiotensin-Converting Enzyme (ACE) inhibitor**, which blocks the enzyme responsible for converting **angiotensin I** to **angiotensin II**. - It does not directly inhibit renin production or activity. *Imidapril* - **Imidapril** is also an **Angiotensin-Converting Enzyme (ACE) inhibitor**, similar to benazepril. - Its mechanism of action involves inhibiting ACE, thereby reducing **angiotensin II** levels, rather than directly inhibiting renin.

Q: Which of the following is NOT a side effect of digitalis?

Vasodilatation. **Vasodilatation** - **Digitalis**, primarily digoxin, is known for its **positive inotropic effect**, increasing myocardial contractility, and for its **vasoconstrictive properties** at higher doses due to sympathetic activation and direct smooth muscle effects, not vasodilatation. - While it can indirectly improve cardiac output and thus tissue perfusion, its direct vascular effects do not typically include widespread vasodilatation. *Ventricular tachycardia* - **Digitalis toxicity** can lead to various arrhythmias, including **ventricular tachycardia**, which is a potentially life-threatening side effect. - This occurs due to increased automaticity and delayed afterdepolarizations in ventricular myocytes. *Nausea and vomiting* - **Gastrointestinal symptoms** such as **nausea and vomiting** are common early signs of digitalis toxicity. - These effects are thought to be mediated by the drug's action on the chemoreceptor trigger zone in the brainstem. *Ventricular Bigeminy* - **Ventricular bigeminy**, characterized by alternating normal and premature ventricular beats, is another classic manifestation of **digitalis toxicity**. - This arrhythmia results from enhanced automaticity and altered conduction properties in the ventricles.

Q: Which of the following is not a cardioselective beta blocker?

Oxprenolol. ***Oxprenolol*** - **Oxprenolol** is a non-selective beta-blocker with **intrinsic sympathomimetic activity (ISA)**, meaning it blocks both β1 and β2 receptors and partially stimulates them. - Its non-selective action means it affects both the heart (β1) and other organs like the lungs (β2), making it less suitable for patients with respiratory conditions. *Nebivolol* - **Nebivolol** is a highly cardioselective beta-blocker that primarily blocks **β1 receptors** and also has **vasodilatory properties** due to nitric oxide release. - Its high selectivity translates to fewer β2-mediated side effects, such as bronchoconstriction. *Atenolol* - **Atenolol** is a **cardioselective beta-blocker** that predominantly blocks **β1 receptors** at therapeutic doses. - This selectivity makes it a common choice for cardiovascular conditions, reducing the risk of bronchospasm compared to non-selective agents. *Betaxolol* - **Betaxolol** is a **cardioselective beta-blocker** primarily used for the treatment of hypertension and glaucoma. - It selectively blocks **β1 adrenergic receptors**, minimizing effects on the lungs compared to non-selective beta-blockers.

Q: Which of the following is a second-generation beta blocker?

Atenolol. ***Atenolol*** - **Atenolol** is a **second-generation beta blocker** characterized by its **cardioselectivity**, meaning it primarily blocks beta-1 receptors in the heart. - This selectively reduces heart rate and contractility with fewer respiratory side effects compared to non-selective agents. *Propranolol* - **Propranolol** is a **first-generation non-selective beta blocker**, meaning it blocks both beta-1 and beta-2 adrenergic receptors. - Its non-selective action can cause significant bronchoconstriction, making it less suitable for patients with respiratory conditions. *Timolol* - **Timolol** is also a **first-generation non-selective beta blocker** commonly used in ophthalmic preparations for glaucoma. - It blocks both beta-1 and beta-2 receptors and does not possess the cardioselectivity of second-generation agents. *Nadolol* - **Nadolol** is another **first-generation non-selective beta blocker** with a long duration of action due to its extensive plasma half-life. - Like other first-generation agents, it lacks cardioselectivity and blocks both beta-1 and beta-2 receptors.

Q: Which beta-1 antagonist is used in congestive cardiac failure?

Metoprolol. ***Metoprolol*** - **Metoprolol succinate** (extended-release formulation) is a selective **beta-1 antagonist** proven to reduce mortality and hospitalizations in **chronic heart failure with reduced ejection fraction (HFrEF)**. - It works by **reducing heart rate, myocardial oxygen demand**, and preventing adverse cardiac remodeling through inhibition of chronic sympathetic activation. - Along with **bisoprolol and carvedilol**, it is one of the **three beta-blockers with proven mortality benefit** in heart failure trials. *Atenolol* - While atenolol is a selective beta-1 antagonist, it **lacks evidence for mortality benefit** in heart failure. - It has **high hydrophilicity** and renal elimination, leading to less favorable pharmacokinetics compared to metoprolol. - More commonly used for **hypertension and angina** rather than heart failure management. *Esmolol* - **Esmolol** is an ultra-short-acting selective beta-1 antagonist used for **acute control of heart rate** in perioperative and critical care settings. - Its **very short half-life (9 minutes)** makes it unsuitable for chronic management of heart failure. - Administered only **intravenously** and requires continuous infusion. *Bisoprolol* - While **bisoprolol is also approved** for heart failure and has proven mortality benefit (CIBIS-II trial), this question likely expects **metoprolol** as the answer given the historical context. - Both bisoprolol and metoprolol are acceptable answers, but **metoprolol** has been more widely studied and is more commonly cited in Indian medical exams. - Bisoprolol has **greater beta-1 selectivity** than metoprolol but similar clinical outcomes in heart failure.

Q: What is the iodine content percentage in amiodarone?

20 - 40%. ***20 - 40%*** - **Amiodarone** is highly lipophilic and contains a significant amount of **iodine**, typically comprising around **37.5%** of its molecular weight. - This high iodine content is responsible for many of its **adverse effects**, particularly those related to thyroid dysfunction. *10 - 20%* - This range is too low; the actual iodine content in **amiodarone** is considerably higher, making it a prominent feature of the drug's chemical structure. - A lower iodine percentage would likely result in fewer **thyroid-related side effects**. *40 - 60%* - While amiodarone has a high iodine content, 40-60% is slightly above the generally accepted range. - Iodine constitutes a substantial but not an overwhelming majority of the drug's molecular mass. *60 - 80%* - This range is significantly higher than the actual iodine content in **amiodarone**. - Such a high percentage would imply an even greater propensity for **iodine-induced adverse effects**.

Q: Which of the following is a centrally acting antihypertensive drug?

Methyldopa. ***Methyldopa*** - **Methyldopa** is a **prodrug** that is converted to **alpha-methylnorepinephrine** in the brain, which then stimulates **alpha-2 adrenergic receptors** in the brainstem. - This stimulation reduces **sympathetic outflow** from the central nervous system, leading to decreased heart rate, stroke volume, and peripheral vascular resistance, thus lowering blood pressure. *Phenoxybenzamine* - **Phenoxybenzamine** is an **alpha-1 and alpha-2 adrenergic receptor antagonist** (non-selective alpha blocker) that primarily acts peripherally. - It causes **vasodilation** by blocking alpha-1 receptors on smooth muscle, which reduces peripheral vascular resistance. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that primarily acts on peripheral beta-adrenergic receptors. - It reduces heart rate and cardiac output by blocking **beta-1 receptors** in the heart and can also affect beta-2 receptors in the lungs and vasculature. *Prazosin* - **Prazosin** is a **selective alpha-1 adrenergic receptor antagonist** that acts primarily on peripheral blood vessels. - It causes **vasodilation** in both arteries and veins by blocking alpha-1 receptors, which reduces both preload and afterload, lowering blood pressure.

Q: Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?

Spironolactone. ***Spironolactone*** - **Spironolactone** was the first potassium-sparing diuretic shown to reduce **cardiac mortality** in patients with **chronic heart failure** in the **RALES trial** (Randomized Aldactone Evaluation Study). - Its beneficial effects in heart failure are primarily attributed to its **aldosterone receptor antagonist** properties, which counteract the harmful effects of aldosterone on the myocardium and vasculature, rather than just its diuretic effect. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that works by directly inhibiting **epithelial sodium channels (ENaC)** in the collecting duct. - While it helps in potassium conservation, it has not been shown to significantly reduce cardiac mortality in chronic heart failure patients in clinical trials. *Triamterene* - **Triamterene** is another potassium-sparing diuretic that also directly inhibits **ENaC** in the collecting duct, similar to amiloride. - Like amiloride, it is used to prevent hypokalemia but lacks evidence for significant **cardiac mortality reduction** in chronic heart failure. *Eplerenone* - **Eplerenone** is a selective **aldosterone receptor antagonist**, similar to spironolactone, with fewer hormonal side effects. - While it has been shown to reduce **cardiac mortality** in chronic heart failure (e.g., in the EMPHASIS-HF trial), it was introduced later than spironolactone and was not the *first* to demonstrate this benefit.

Question 1

Which of the following statements about hypolipidemic drugs is false?

Accepted Answer

Cholesterol reducing drugs are contraindicated in child less than 8 years

Answer

Gemfibrozil causes myopathy

Answer

Gemfibrozil can increase myopathy caused by statins

Answer

Lovastatin can cause hepatic dysfunction

Question 2

All of the following are adverse effects of nicotinic acid except:

Accepted Answer

Pancreatitis

Answer

Liver dysfunction

Answer

Vasodilation

Answer

Hyperpigmentation

Question 3

Which of the following is a renin inhibitor?

Accepted Answer

Remikiren

Answer

Losartan

Answer

Benazepril

Answer

Imidapril

Question 4

Which of the following is NOT a side effect of digitalis?

Accepted Answer

Vasodilatation

Answer

Nausea and vomiting

Answer

Ventricular Bigeminy

Answer

Ventricular tachycardia

Question 5

Which of the following is not a cardioselective beta blocker?

Accepted Answer

Oxprenolol

Answer

Nebivolol

Answer

Atenolol

Answer

Betaxolol

Question 6

Which of the following is a second-generation beta blocker?

Accepted Answer

Atenolol

Answer

Timolol

Answer

Nadolol

Answer

Propranolol

Question 7

Which beta-1 antagonist is used in congestive cardiac failure?

Accepted Answer

Metoprolol

Answer

Atenolol

Answer

Esmolol

Answer

Bisoprolol

Question 8

What is the iodine content percentage in amiodarone?

Accepted Answer

20 - 40%

Answer

10 - 20%

Answer

40 - 60%

Answer

60 - 80%

Question 9

Which of the following is a centrally acting antihypertensive drug?

Accepted Answer

Methyldopa

Answer

Phenoxybenzamine

Answer

Propranolol

Answer

Prazosin

Question 10

Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?

Accepted Answer

Spironolactone

Answer

Amiloride

Answer

Triamterene

Answer

Eplerenone

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?